Technology firm Jolly Good and Teijin Pharma have begun a partnership to develop virtual reality digital therapeutics (VR DTx) for major depressive disorder.
Just days after Telix priced a $200 million initial public offering (IPO) in the US, the Australian radiopharmaceutical specialist has abandoned the plan.